Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders

Susceptibility to glioma

A glioma is a tumor of the central nervous system that starts from glia cells. Susceptibility may be associated with variants in the IDH1 gene.

Systematic

Hereditary neurological disorders
Alzheimer disease
Arts syndrome
Autism
Autosomal dominant cerebellar ataxia, deafness and narcolepsy
Autosomal recessive spastic paraplegia type 44
Brain malformations with urinary tract defects
Brain small vessel disease with hemorrhage
Brunner syndrome
Charcot-Marie-Tooth disease
Congenital insensitivity to pain with anhidrosis
Hereditary benign chorea
Hereditary distal motor neuron neuropathy type 5A
Hereditary muscle diseases
Hereditary sensory and autonomic neuropathy type 2A
Hereditary sensory neuropathy type 1E
Hypokalemic periodic paralysis 1
Hypomyelinating Leukodystrophy 2
Idiopathic basal ganglia calcification 1
Intellectual disability-severe speech delay-mild dysmorphism syndrome
Migraine
Nemaline myopathy 5
Porencephaly
Rett syndrome
Severe neonatal-onset encephalopathy with microcephaly
Spastic paraplegia 17 with amyotrophy of hands and feet
Susceptibility to glioma
IDH1
Vascular dementia
X-linked syndromic mental retardation 13

References:

1.

Piccirillo SG et al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

[^]
2.

Singh D et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma.

[^]
3.

Jones DT et al. (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

[^]
4.

Parsons DW et al. (2008) An integrated genomic analysis of human glioblastoma multiforme.

[^]
5.

Yan H et al. (2009) IDH1 and IDH2 mutations in gliomas.

[^]
6.

Dubbink HJ et al. (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

[^]
7.

Bralten LB et al. (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.

[^]
8.

Flavahan WA et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas.

[^]
9.

None (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

[^]
10.

Thuwe I et al. (1979) Familial brain tumour.

[^]
11.

de Tribolet N et al. (1979) Familial gliomas.

[^]
12.

von Motz IP et al. (1977) Astrocytoma in three sisters.

[^]
13.

Clarenbach P et al. (1979) Simultaneous clinical manifestation of subependymoma of the fourth ventricle in identical twins. Case report.

[^]
14.

Ransom DT et al. (1992) Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas.

[^]
15.

von Deimling A et al. (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.

[^]
16.

Wong AJ et al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas.

[^]
17.

Olopade OI et al. (1992) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas.

[^]
18.

Sainati L et al. (1992) Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas?

[^]
19.

Griffin CA et al. (1992) Chromosome abnormalities in low-grade central nervous system tumors.

[^]
20.

Bigner SH et al. (1990) Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma.

[^]
21.

Duhaime AC et al. (1989) Simultaneous presentation of glioblastoma multiforme in siblings two and five years old: case report.

[^]
22.

Fujimoto M et al. (1989) Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme.

[^]
23.

Geraghty AV et al. (1989) Prenatal diagnosis of fetal glioblastoma multiforme.

[^]
24.

el-Azouzi M et al. (1989) Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas.

[^]
25.

Chemke J et al. (1985) Familial glioblastoma multiforme without neurofibromatosis.

[^]
26.

Heuch I et al. (1986) Glioblastoma multiforme in three family members, including a case of true multicentricity.

[^]
27.

Honan WP et al. (1987) Familial subependymomas.

[^]
28.

Bigner SH et al. (1988) Specific chromosomal abnormalities in malignant human gliomas.

[^]
29.

Munoz DG et al. (1988) Cerebral malignant tumors with ependymal and choroidal differentiation in two siblings.

[^]
30.

Vieregge P et al. (1987) Familial glioma: occurrence within the "familial cancer syndrome" and systemic malformations.

[^]
31.

Leblanc R et al. (1986) Familial mixed oligodendrocytic-astrocytic gliomas.

[^]
32.

Henn W et al. (1986) Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines.

[^]
33.

Isamat F et al. (1974) Genetic implications of familial brain tumors.

[^]
34.

Armstrong RM et al. (1969) Familial gliomas.

[^]
35.

None (1971) Deaths from childhood leukemia and solid tumors among twins and other sibs in the United States, 1960-67.

[^]
36.

Downward J et al. () Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

[^]
37.

Schianchi P et al. (1980) Familial brain tumors: rhombencephalon-astrocytoma grade I in father and son.

[^]
38.

Chen P et al. (1995) Constitutional p53 mutations associated with brain tumors in young adults.

[^]
39.

Fults D et al. (1993) Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme.

[^]
40.

Ryken TC et al. (1994) Familial occurrence of subependymoma. Report of two cases.

[^]
41.

Kyritsis AP et al. (1994) Germline p53 gene mutations in subsets of glioma patients.

[^]
42.

Karlbom AE et al. (1993) Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10.

[^]
43.

Bögler O et al. (1995) The p53 gene and its role in human brain tumors.

[^]
44.

von Deimling A et al. (1995) Molecular pathways in the formation of gliomas.

[^]
45.

Kimmelman AC et al. (1996) Loss of heterozygosity of chromosome 10p in human gliomas.

[^]
46.

Chattopadhyay P et al. (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.

[^]
47.

Mollenhauer J et al. (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours.

[^]
48.

Chernova OB et al. (1998) A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors.

[^]
49.

Simons A et al. (1999) Isolation and characterization of glioblastoma-associated homozygously deleted DNA fragments from chromosomal region 9p21 suggests involvement of multiple tumour suppressor genes.

[^]
50.

Smith JS et al. (2000) A transcript map of the chromosome 19q-arm glioma tumor suppressor region.

[^]
51.

Frederick L et al. (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

[^]
52.

Ueki K et al. (1997) ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3.

[^]
53.

Tachibana I et al. (2000) Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.

[^]
54.

Holland EC et al. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

[^]
55.

Reilly KM et al. (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.

[^]
56.

Esteller M et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

[^]
57.

Malmer B et al. (2001) Genetic epidemiology of glioma.

[^]
58.

de Andrade M et al. (2001) Segregation analysis of cancer in families of glioma patients.

[^]
59.

Nishimoto A et al. (2001) Functional evidence for a telomerase repressor gene on human chromosome 10p15.1.

[^]
60.

Marie Y et al. (2001) OLIG2 as a specific marker of oligodendroglial tumour cells.

[^]
61.

Hoang-Xuan K et al. (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.

[^]
62.

Jin W et al. (2000) p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.

[^]
63.

Pollack IF et al. (2002) Expression of p53 and prognosis in children with malignant gliomas.

[^]
64.

Gutmann DH et al. (2002) Mouse glioma gene expression profiling identifies novel human glioma-associated genes.

[^]
65.

Cartron PF et al. (2002) The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients.

[^]
66.

Staal FJ et al. (2002) A novel germline mutation of PTEN associated with brain tumours of multiple lineages.

[^]
67.

Hu J et al. (2002) High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours.

[^]
68.

Leuraud P et al. (2003) Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1.

[^]
69.

KJELLIN K et al. (1960) The occurrence of brain tumors in several members of a family.

[^]
70.

PARKINSON D et al. (1962) Oligodendrogliomas. Simultaneous appearance in frontal lobes of siblings.

[^]
71.

Yokota T et al. (2003) A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor.

[^]
72.

Hegi ME et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

[^]
73.

Aldape KD et al. (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.

[^]
74.

Reilly KM et al. (2004) Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

[^]
75.

Stupp R et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

[^]
76.

Hegi ME et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma.

[^]
77.

Liang Y et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.

[^]
78.

Mellinghoff IK et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

[^]
79.

Bao S et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

[^]
80.

Pfister S et al. (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

[^]
81.

Savaskan NE et al. (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema.

[^]
82.

Blumenthal DT et al. (2008) Familiality in brain tumors.

[^]
83.

Zheng H et al. (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.

[^]
84.

El Hallani S et al. (2009) TP53 codon 72 polymorphism is associated with age at onset of glioblastoma.

[^]
85.

De Carli E et al. (2009) IDH1 and IDH2 mutations in gliomas.

[^]
86.

Yu J et al. (2009) Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

[^]
87.

Carro MS et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours.

[^]
88.

Kyritsis AP et al. (2010) Inherited predisposition to glioma.

[^]
89.

Labussière M et al. (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

[^]
90.

Sheng Z et al. (2010) A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

[^]
91.

Johnson RA et al. (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma.

[^]
92.

Wang R et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium.

[^]
93.

Ricci-Vitiani L et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

[^]
94.

Bredel M et al. (2011) NFKBIA deletion in glioblastomas.

[^]
95.

Bettegowda C et al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

[^]
96.

Schwartzentruber J et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

[^]
97.

Wu G et al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.

[^]
98.

Muller FL et al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer.

[^]
99.

Lewis PW et al. (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.

[^]
100.

Frattini V et al. (2013) The integrated landscape of driver genomic alterations in glioblastoma.

[^]
101.

Parker M et al. (2014) C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

[^]
102.

Mack SC et al. (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.

[^]
103.

Funato K et al. (2014) Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.

[^]
104.

Kim D et al. (2015) SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.

[^]
105.

et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

[^]
106.

Eckel-Passow JE et al. (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

[^]
107.

Jahani-Asl A et al. (2016) Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

[^]
108.

OMIM.ORG article

Omim 137800 [^]
Update: April 29, 2019